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Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is the most frequent disease associated with abnormal liver
tests that is characterized by a wide spectrum of liver damage, ranging from simple macro vesicular steatosis to
steatohepatitis (NASH), cirrhosis or liver carcinoma. Liver biopsy is the most precise test to differentiate NASH from
other stages of NAFLD, but it is an invasive and expensive method. This study aimed to create a clinical laboratory
score capable of identify individual with NASH in severely obese patients submitted to bariatric surgery.
Methods: The medical records from 66 patients submitted to gastroplasty were reviewed. Their chemistry profile,
abdominal ultrasound (US) and liver biopsy done during the surgical procedure were analyzed. Patients were
classified into 2 groups according to liver biopsy: Non-NASH group - those patients without NAFLD or with grade I,
II or III steatosis; and NASH group - those with steatohepatitis or fibrosis. The t-test was used to compare each
variable with normal distribution between NASH and Non-NASH groups. When comparing proportions of
categorical variables, we used chi-square or z-test, where appropriate. A p-value < 0.05 was considered statistically
significant.
Results: 83% of patients with obesity grades II or III showed NAFLD, and the majority was asymptomatic. Total
Cholesterol (TC)≥200 mg/dL, alanine aminotransferase (ALT) ≥30, AST/ALT ratio (AAR)≤ 1, gammaglutaril-transferase
(gGT)≥30 U/L and abdominal US, compatible with steatosis, showed association with NASH group. We proposed 2
scores: Complete score (TC, ALT, AAR, gGT and US) and the simplified score, where US was not included. The
combination of biochemical and imaging results improved accuracy to 84.4% the recognition of NASH (sensitivity
70%, specificity 88.6%, NPV 91.2%, PPV 63. 6%).
Conclusion: Alterations in TC, ALT, AAR, gGT and US are related to the most risk for NASH. The combination of
biochemical and imaging results improved accuracy to 84.4% the recognition of NASH. Additionally, negative final
scores exclude the presence of an advanced illness. Using this score, the severity of fatty liver infiltration would be
predicted without the risks associated with hepatic biopsy.
Background
With the increased incidence of obesity worldwide, non-
alcoholic fatty liver disease (NAFLD) has become a
growing problem. NAFLD is a common and emergent
condition now recognized as the most frequent cause of
abnormal liver tests, especially in obese individuals [1,2].
It is characterized by a wide spectrum of liver damage,
ranging from simple macro vesicular steatosis to steato-
hepatitis (NASH), cirrhosis or liver carcinoma [2-5]. In
the general population, the estimated prevalence ranges
from 3% to 24%, with most estimates in the 6% to 14%
range. NAFLD is extremely common among patients
undergoing bariatric surgery, ranging from 84% to 96%,
these patients, 25% to 55% have NASH, 34% to 47%
have fibrosis, and 2% to 12% have bridging fibrosis or
cirrhosis [4].
Since the majority of NAFLD patients are asympto-
matic, investigation usually begins after detection of
abnormal liver enzymes on routine evaluation [4].
Serum aspartate aminotransferase (AST) and, more
commonly, alanine aminotransferase (ALT) show mild
to moderate elevation. The correlation with gammaglu-
taril-transferase (gGT) remains uncertain. Therefore,
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there is no overall correlation between the degree of
liver enzyme elevation and the level of damage observed
on histopathological analysis, beyond most of the
patients with NAFLD show normal liver chemistries.
NAFLD appears to be most strongly associated with
obesity and insulin resistance. There is some correlation
between the severity of NAFLD and other features of
metabolic syndrome, such as high triglycerides and low
HDL, suggesting that NAFLD is an hepatic manifesta-
tion of metabolic syndrome [6-9].
Nonalcoholic steatohepatitis (NASH), which is the
most severe histological form of NAFLD, is emerging as
the most common clinically important form of liver dis-
ease in diabetes, obese patients and metabolic syndrome
[6,10]. NASH has been associated with slight elevation
of liver enzymes (mostly ALT and g-GT) [10].
The “gold standard” for the diagnosis of NASH is liver
biopsy, which allows us to differentiate simple bland
steatosis from NASH [3,11]. However, liver biopsy is an
expensive and invasive method associated with a low,
but important procedure risk. Ultrasound (US), compu-
terized tomography (CT), Magnetic resonance imaging
(MRI), and H magnetic resonance spectroscopy (H
MRS) are noninvasive methods and should be preferred.
One limitation being that US does not provide reliable
quantitative information [11]. Both the CT and MRI
techniques are nonspecific and can be affected by pro-
cesses such as excessive glycogen storage, edema and
inflammation [11].
The aim of our study was to create a clinical labora-
tory score capable of identify individual with most risk
for NASH in severely obese patients submitted to baria-
tric surgery. Using this score, the severity of fatty liver
infiltration would be predicted without the risks asso-
ciated with hepatic biopsy.
Methods
We reviewed the medical records of all patients sub-
mitted to gastroplasty at the Hospital da Irmandade da
Santa Casa de Misericordia de São Paulo, between March
2004 and April 2006 and who had intra-operative liver
biopsies at the time of Roux-en-Y distal gastric bypass.
The inclusion criteria for the study were: patients with
BMI ≥ 35 Kg/m2 that underwent the surgical treatment
without any other adventitious causes of hepatopathy as
alcoholism or viral hepatitis. The exclusion criteria were
the ingestion of more than 20 g of alcohol per day or reg-
ular ingestion of drugs known to produce steatosis (glu-
cocorticoids, tamoxifen, amiodarone) or any other
condition with concomitant liver disease (viral hepatitis,
autoimmune hepatitis, primary biliary cirrhosis, hemo-
chromatosis or Wilson’s disease). According to these cri-
teria, 66 patients were selected for the study. The
following data were evaluated: preoperative conditions,
gender, age, body mass index (BMI), presence of hyper-
tension and diabetes mellitus, chemistry profile including
aspartate aminotransferase (AST), gammaglutaril-trans-
ferase (gGT), alkaline phosphatase (ALP), total choles-
terol (TC), low density lipoprotein (LDL), high density
lipoprotein (HDL), triglycerides, fasting glucose (FG) and
abdominal US.
The diagnosis of metabolic syndrome followed the cri-
teria established by the International Diabetes Federa-
tion (IDF) 2005 [12].
NAFLD was diagnosed by ultrasonography using an
abdominal probe at 2-5 MHz. Longitudinal, sub costal,
ascending, and oblique scans were performed. The ultra-
sonographic criteria that were used to diagnose fatty
liver included liver and kidney echo discrepancy, pre-
sence of increase liver echogenicity (bright), echo pene-
tration into the deep portion of the liver, and clarity of
liver blood vessel structures.
The hepatic biopsy was performed intra-operatively
and analyzed according to Brunt criteria [13], as is
shown in Table 1. We classified our patients in two
groups: Non-NASH group (patients without NAFLD or
with grade I, II or III steatosis without hepatitis) and
NASH group (patients with steatohepatitis or fibrosis).
Demographic, laboratory and imaging data were com-
pared between both groups.
The t-test was used to compare each variable with
normal distribution between NASH and Non-NASH
groups. When comparing proportions of categorical
variables, we used chi-square or z-test, where appropri-
ate. A p-value < 0.05 was considered statistically
significant.
In order to propose a score system that is simple to
use, we aimed to define cut-off levels for variables that
would improve the model. We evaluated all continuous
variables with p < 0.300 in the group comparisons using
ROC (Receiver Operating Characteristics) curve analysis,
to evaluate the sensitivity and specificity of cut-off levels.
Table 1 Classification into 2 groups according to liver
biopsy: NASH and Non-NASH
Brunt’s score n (%) Study Score
Absent NAFLD 11 (11.6) Non-NASH Group
Steatosis I 21 (31.8)
Steatosis II 11 (16.6)
Steatosis III 10 (15.1)
Fibrosis I 9 (13.6) NASH Group
Fibrosis II 3 (4.5)
Fibrosis III 0 (0)
Fibrosis IV 1 (1.5)
Total 66 (100)
Patients without NAFLD or with steatosis, grade I, II or II were classified as
Non-NASH group. Patients with NASH were classified as NASH group. The
classification of NAFLD was according to Brunt’s score.
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We included in our models all variables that presented
the average of sensitivity and specificity of 60% or above.
If both AST/ALT ratio (AAR) and one of the enzymes
that compose the index were to be included in the mod-
els, a kappa statistics (agreement) above 70% would
indicate that only one would be necessary for the model.
These variables and cut-off levels were employed to
classify patient’s results and used to perform chi-square
tests. We used 2 × 2 tables to calculate sensitivity, speci-
ficity, positive (PPV) and negative (NPV) predictive
values. We used SPSS 17.0 (SPSS, USA) and MS-Excel
2003 (Microsoft, USA) to perform calculations.
Results
We evaluated 66 individuals (11 males), with mean (SD)
of 40.7(10.9) years of age and BMI of 46.4(6.5) kg/m2.
Metabolic syndrome was present in 37 patients and type
2 DM in 10 subjects (7 women).
Males presented higher BMI (51.2 ± 5.3 kg/m2) than
women (45.6 ± 6.3, p = 0.009, t-test), and similar age
(males 38.8 y ± 9.3; women: 41.1 ± 11, p = 0.484, t-test).
The proportion of cases with metabolic syndrome was
also similar (males 7/11 cases; women 30/44 cases, p =
0.775, chi-square test).
Metabolic syndrome occurrence was similar in the
NASH group (8/12 cases) when compared to Non-
NASH group (29/43; p = 0.960, chi-square test). All
patients presented abdominal waist values above the
standards established. Age, BMI, sex, waist circumfer-
ence, hypertension, lipid and hepatic enzymes (AST and
ALT) measurements showed no association with NASH.
However, age, TC, AST, ALT, the AST/ALT ratio
(AAR) and gGT hap p values below 0.3 (Table 2) and a
ROC curve analysis was performed to establish cut-off
values (Table 3).
An abdominal US was available for 62 patients, pre-
senting normal (or non-steatosis) more frequently in
Non-NASH (26/49) than in NASH (3/13; p = 0.048, chi-
square). Abdominal US presented sensitivity and specifi-
city of 76.9% and 46.9%, respectively, to identify NASH.
Using ROC curve analysis, we established the follow-
ing cut-off levels (equal or above being indicative of
NASH): TC of 200 mg/dL, ALT of 30 IU/L and gGT of
30 IU/L (Figure 1). For AAR, a value equal of below 1
was indicative of NASH. Although the area under curve
(AUC) of the ROC curve was not always significant
(table 3), these tests presented sensitivities ranging from
67% to 83% with specificity of 44% to 71% (average of
sensitivity and specificity ranged from 62% to 71%). The
kappa statistics of AAR ≤ 1 and ALT ≥ 30 IU/L in
defining NASH patients was 29.4% (p = 0.201), therefore
both were included in the model.
Both age and AST were not included in the model for
failing to present a cut-off level with average of sensitivity
and specificity of 60% or greater. Age of 36.5 years pro-
vided the best discrimination with sensitivity of 69.2%
and specificity of 43.4%. The best cut-off for AST was 17
IU/L with sensitivity of 91.7% and specificity of 22.2%.
Low accuracy prevents the use of each test alone.
Therefore, we decided to evaluate two score systems
(with and without US, as complete and simplified
scores). In the complete score, we assigned 1 point for
each of the following parameters: TC ≥200 mg/dL; AAR
≤ 1; ALT ≥30 IU/L; gGT ≥30 U/L and steatosis at
abdominal US, with a total of 5 possible points. In the
simplified score, US were not evaluated; therefore, a
total of 4 points was possible.
Both score systems were evaluated using ROC analysis
(Figure 1). The complete score could be evaluated in 10
NASH patients and 35 Non-NASH patients (Figure 2) and
presented an area under curve of 82.4% (CI 95%:67% -
97.8%, p = 0.002, ROC). The simplified score was







Gender: % women 84.9 76.9 0.503
Age ( years) 39.8 (± 10.4) 44.6 (± 12.5) 0.216*
BMI ( Kg/m2) 46.3 (± 6.45) 47.0 (± 6.72) 0.714
HAS (% positive) 58.5 46.2 0.423
DM (% positive) 13.2 23.1 0.374
CT (mg/dL) 195.4 (± 37.28) 210.2 (± 22.3) 0.094*
LDL (mg/dL) 120 (± 35) 125.8 (± 22) 0.488
TG (mg/dL) 141.3 (± 57.5) 163 (± 111) 0.544
HDL (mg/dL) 49.0 (± 11.9) 48.9 (± 7.9) 0.968
FG (mg/dL) 103.2 (± 23.9) 100.5 (± 11.6) 0.589
AST (IU/L) 23.6 (± 9.2) 31.6 (± 22.4) 0.248*
ALT (IU/L) 24.5 (± 13.1) 44.8 (± 45) 0.151*
GGT (IU/L) 38.2(24.4) 46.5(18.5) 0.229*
AAR 1.000 0.7677 0.047**
ALP (IU/L) 170.2 (± 79.7) 159.6 (± 56.5) 0.659
SM (% positive) 67.4 66.7 0.960
US (% abnormal) 47 77 0.048**
Data is expressed as Mean ± SD (except for AAR that has a non-parametric
distribution).
Table 3 Cut-off and ROC curve analysis of each marker
that was included in the score systems
Test Cut-off AUC (95% interval) P Sensitivity Specificity






ALT 30 IU/L 70.1%
(53 - 87%)
0.034 66.7% 71.1%
GGT 30 IU/L 65.5%
(49 - 82%)
0.084 90.9% 44.2%
US Abnormal n/a n/a 76.9% 46.9%
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evaluated in 10 NASH patients and 36 Non-NASH
patients (Figure 3) and presented an area under curve of
73.1% (CI 95%= 54.1% - 92.0%, p = 0.027) to identify
NASH. In table 4, we show sensitivity, specificity, positive
and negative predictive values with different points in both
scores. When no points are obtained, regardless of the
score system employed, sensitivity and positive predictive
value to identify NASH are equal to zero.
Discussion
Despite the high prevalence and severity of hepatic ill-
ness, NAFLD remains underdiagnosed. This is in part
because of limitations in clinical diagnosis as a conse-
quence of few symptoms, lack of accurate laboratory
markers and restrictive indication of hepatic biopsy [1-3].
Thus, identifying noninvasive approaches for distin-
guishing simple hepatic steatosis from NASH in patients
with NAFLD is critical given the increasing incidence
and prevalence of this disease in our society.
Liver biopsy is the only way to confirm or exclude the
diagnosis of NASH [3,11], giving valuable information
regarding staging, prognosis and progress of this patho-
logic condition. However, serious complications have
been communicated in percutaneous liver biopsy, they
included retroperitoneal bleeding, and bile leak and, as
many as one third of patients experiment strong pain
[14,15]. The major contraindication to percutaneous
liver biopsy is significant coagulopathy and relative con-
traindication to this procedure is obesity. Therefore,
these kinds of liver biopsies not only incur increased
risk to the patient, but also it is not possible to perform
liver biopsies in all patients with NAFLD to exclude the
severe form of this disease. Recent developments of
laparoscopy bariatric surgery for obesity have increased
the number of intraoperative liver biopsies.
Our study demonstrated that 83% of patients with
obesity grades II or III showed NAFLD, and the major-
ity was asymptomatic.
Some studies have shown that obesity is a metabolic
illness closely associated with both steatosis and NASH,
and the severity of the hepatic illness is related to the
increase of BMI. In disagreement with this statement of
Dixon et al [16], Beymer et al [17] showed that BMI did
not differ between groups with and without NASH in
Figure 1 ROC curves showing the sensitivity and specify to
identify severe steatosis.
Figure 2 Number of patients with NASH according to the
number of points of a simplified score system.
Figure 3 Number of patients with NASH according to the
number of points in complete score system.
Table 4 Sensitivity, specificity, positive and negative
predictive values and accuracy to identify NASH at liver
biopsy




















70 10 70 10
Specificity
(%)
75 100 88.6 100
PPV (%) 43.8 100 63.6 100
NPV (%) 90 80 91.2 79.5
Accuracy
(%)
73.9 80.4 84.4 80
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morbidly obese patients, and that insulin resistance,
hypertension, and elevated ALT were independently pre-
dicted the presence of NASH. In our study BMI did not
differ between groups with and without NASH.
Serum liver enzyme abnormalities are primarily
restricted to elevations of ALT. The majority of eleva-
tions are mild (< 5× the upper normal limit), and exist
in all degrees of NAFLD. However, there isn’t correla-
tion between the degree of liver enzyme elevation and
the level of damage observed on histopathological analy-
sis, as has been seeing in most of the patients with
NAFLD that present normal laboratory values, being
not useful as a differential marker. Our study ALT was
correlated to the severity of the hepatic damage.
In contrast to patients with alcohol-induced liver dis-
ease, the AST/ALT ratio (AAR) among NAFLD patients
is usually less than 1 [3]. In our study, we confirmed
this finding. Evidence that this ratio may reverse with
advanced fibrosis or cirrhosis has been reported
[3,11,15]. AAR greater than 1 can be an independent
risk factor for advanced fibrosis among patients with
biopsy-proven NASH according some studies [18,19].
The role of gGT, as a molecular marker for disease
severity and diagnostics is still obscure in NAFLD.
Nevertheless, Sakugawa’s [20] data showed that was a
significant difference between gGT level and the severity
of liver fibrosis. Our results show that gGT ≥ 30 IU/L is
an adequate marker of NASH.
Thus, considering the markers of liver damage, gGT,
ALT and AAR were correlated to the severity of the
hepatic damage. We believe that aminotransferases
abnormalities probably occur at an earlier stage, differ-
ent from gGT that would require a greater hepatic
damage to be altered.
High fasting glucose levels and lipid alterations, such
as hypertriglyceridemia and low HDL are laboratory
markers of insulin resistance [21,22]. In our study, these
markers presented no correlation with the severity of
the liver disease.
The sensitivity and specificity of US is considered rea-
sonable for detecting liver steatosis. However, the sensi-
tivity of US might be lower in mild fat infiltration and is
difficult in the morbidly obese patient because of exces-
sive fat which might take us to an unreliable result [3].
Liang et al [23] disagree with the above, since they have
shown that US use may be acceptable in the morbidly
obese patients. We would argue that as US depends of
the equipment available, the software used for analysis
and the operator, satisfaction with the obtained results
can vary between different centers. Our analysis did not
consider the degree of hepatic alteration, but simply
showed whether steatosis was present. US alone was
able to detect 76.9% of the cases but presented a low
specificity (46.9%), however, when associated with other
parameters, such as the 5-points (complete) score, its
sensitivity increased to 88.6% while maintaining reason-
able sensitivity (70%) for the more serious cases. There-
fore, in severely obese patients, in whom US specificity
is lower, the inclusion of the score significantly
improved the identification of these cases. Other scores
have been described aiming at the correlation between
isolated laboratory findings, in the attempt of improving
the non-invasive diagnosis of NAFLD.
Palekar [19] proposed a diagnostic model using both
clinical and laboratory data to enhance distinguishing
patients with simple steatosis from those with NASH.
Patients with three or more of the following characteristics
are more likely to have NASH than simple steatosis: female
gender, age ≥ 50 years, AST > 45 IU/L, BMI ≥ 30 Kg/m2,
AAR ≥ 0.8 and hyaluronic acid ≥ 55 mcg/L. ROC curve
analysis showed accuracy of 0.763. The presence of three
or more factors showed sensitivity, specificity, PPV and
NPV of 73.7%, 65.7%, 68.2% e 71.4%, respectively.
Sakugawa [20] showed that type VI collagen 7S
domain ≥ 5.0 ng/mL and hyaluronic acid ≥ 43 ng/mL
were markers of liver fibrosis that had a high positive
predictive value ( 86% and 92%, respectively) and high
negative predictive value ( 84% and 78%, respectively).
Angulo [18] identified independent predictors of liver
fibrosis: age > 45 years, the presence of obesity or type 2
diabetes mellitus, and AST/ALT ratio > 1.
In this study we propose a diagnostic model using
clinical, laboratory and imaging data to improve the dif-
ferential diagnosis of patients who belong to the Non-
NASH group from those are part of NASH group.
Patients with three or more of the following characteris-
tics are more likely to have NASH (sensitivity 70%, spe-
cificity 75%, NPV 90%, PPV 43.8%): TC ≥ 200 mg/dL,
ALT ≥ 30 IU/L, gGT ≥ 30 IU/L and AAR ≤ 1. If we add
the US, and the patient shows four or more of the five
criteria, the sensitivity is 70%, specificity is 88.6%, NPV
91.2% and PPV 63.6%. This composite index seems to
be a good discriminator to identify the NAFLD patients
with more severe disease.
As can be seen here, the sensitivity, specificity, PPV
and NPV obtained by the measurements we propose in
this study are better than the ones previously reported.
All patients from NASH group presented at least one
point in the simplified score and complete score, sug-
gesting very low risk of an advanced hepatic illness in
negative scores.
Identifying patients at risk may assist physicians in
planning the diagnosis and treatment, selecting those
patients who really need liver biopsy. Furthermore, addi-
tional stratification for advanced NAFLD may be helpful
to identify those patients who are at risk for disease pro-
gression and could benefit from future medical therapy
or enrollment in clinical trials.
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The score system suggested by this study can be easily
applied. It routine biochemical tests (TC, ALT, AAR
and gGT) in its simplified version, or it can be accompa-
nied by US in the complete version. It is highly sensitive
for advanced hepatic illnesses and can provide the prac-
titioner with information to offer a more adequate
treatment.
The present study provided evidence of applying a
score test to evaluated non alcoholic liver disease in
obese patients. However, our study presents some lim-
itations such as, the reduced number of patients. We
also studied subjects with obesity grade III, and some of
them are metabolic healthy, meaning that they don’t
have any component of metabolic syndrome. Future
study introducing an independent test group in order to
validate the proposed score test would improved the
present study.
Conclusion
In conclusion, alterations in TC, ALT, AAR, gGT and
US are related to a higher risk for NASH. The combina-
tion of biochemical and imaging results improved accu-
racy to 84.4% the recognition of NASH (sensitivity 70%,
specificity 88.6%, NPV 91.2%, PPV 63. 6%). Additionally,
negative final scores exclude the presence of an
advanced illness. Although not essential, US is simple,
non-invasive and a low-cost method, which can improve
the score system in the can diagnosis of NASH or in
the recognition of co-morbidities. Using this score, the
severity of fatty liver infiltration would be predicted
without the risks associated with hepatic biopsy.
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